CTOs on the Move

International Center for Toxicology and Medicine

www.ictm.com

 
International Center for Toxicology and Medicine is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.ictm.com
  • 2301 Research Blvd
    Rockville, MD USA 20850
  • Phone: 301.519.0300

Executives

Name Title Contact Details

Similar Companies

CERTUS PHARMACEUTICALS

CERTUS PHARMACEUTICALS is a Berkeley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amador Bioscience

Amador Bioscience, a leading partner for successful new drug development, provides global-standard translational sciences and clinical pharmacology services to clients ranging from cutting-edge biotech start-ups to multinational pharmaceutical companies. Founded in 2018 and supported by prominent institutional investors, Amador Bioscience operates in multiple sites, Pleasanton, CA, Ann Arbor, MI, Germantown, MD, Richmond, VA, Hangzhou and Shanghai, China, and Limburg.

Jim's Pharmacy and Gifts

Jim's Pharmacy and Gifts is a Port Angeles, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sovereign Pharmaceuticals

Sovereign Pharmaceuticals is your ideal CDMO partner for your pharma product development, formulation, fill/finish, packaging & commercial manufacturing needs.

Dragon Pharmaceuticals

Dragon Pharmaceuticals Inc. (OTC-BB: Drug) is an international biotech company headquartered in Vancouver, Canada, with production and R&D facilities in Nanjing, China and 160 employees worldwide. The Company develops and commercializes human proteins for therapeutic use. Using superior and proprietary DNA vector technology, Dragon is able to produce high yields of quality protein drugs at low costs and high margins. Dragon is one of the world`s largest producers of Epoetin Alfa, or EPO, a therapeutic protein used to treat anemia related to kidney failure, chemotherapy, and surgery. Dragon`s EPO is approved and being marketed for use in chronic renal failure in China, Egypt, India and Peru. Additional regulatory submissions are in progress throughout Central and Eastern Europe, Southeast Asia, Latin America and the Middle East.